Loading organizations...
Based in Brisbane, Australia, Gelomics develops 3D cell culture technologies, including tunable extracellular matrices, to create in vitro human tissue models for drug discovery and disease modeling. The biotechnology company provides its products to more than 250 academic laboratories, pharmaceutical companies, and contract research organizations across 23 global markets. Gelomics has secured capital through multiple financing rounds, including a $2.2 million pre-seed raise and a subsequent $3.2 million investment backed by Jelix Ventures, Queensland Investment Corporation, and AngelLoop. Operating with a team of up to 25 employees, the firm utilizes its proprietary LunaGel and LunaX systems to reduce preclinical study costs and provide an alternative to animal testing. The Australian enterprise was founded in 2018 as a spin-off from the Queensland University of Technology by Christoph Meinert, Peter Levett, Dietmar Hutmacher, and Travis Klein.
Gelomics has raised $2.0M across 1 funding round.
Gelomics has raised $2.0M in total across 1 funding round.
Gelomics has raised $2.0M in total across 1 funding round.
Gelomics's investors include Blackbird Ventures Australia, Jelix Ventures.
Gelomics has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in July 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2024 | $2M Seed | — | Blackbird Ventures Australia, Jelix Ventures | Announced |
Gelomics is an Australian deep-tech biotechnology company founded in 2018 and headquartered in Brisbane, Queensland, that revolutionizes drug development by replacing animal testing with human-relevant 3D cell culture technologies integrated into an AI-powered platform.[1][3] It designs and manufactures the LunaX System, which combines proprietary hydrogels, advanced photopolymerisation devices, and AI-driven software to enable pharmaceutical companies, CROs, academic institutions, and research organizations worldwide to grow functional human tissue models in vitro, accelerating safer and more effective therapies.[1][2][4] Serving biotech, pharma R&D, CMOs, and CROs across 23+ international markets in North America, Europe, Asia-Pacific, and the Middle East, Gelomics solves key pain points like ethical concerns, high costs, low predictive accuracy of animal models, and slow drug discovery timelines, with strong growth evidenced by KPMG Tech Innovator 2024 recognition and Global Tech Innovator 2024 finalist status.[1][2]
Gelomics was founded in 2018 by Christoph Meinert (CEO & Co-Founder), who leads the company with a focus on pioneering ethical drug development, as highlighted in his representation of Australia as a Global Tech Innovator 2024 finalist.[1][2] The idea emerged from expertise in biomaterials for tissue engineering; CTO Peter (PhD holder) developed the core technology behind early products, bringing experience in capital raising, commercialization, and team scaling as a chartered chemical engineer.[3] Early traction built on this foundation, with rapid expansion post-2024 awards, securing clients among multinational pharmas and institutions while advancing the LunaX platform to bypass animal testing limitations.[1][2]
The leadership team humanizes the mission: Dr. Pawel Mieszczanek (engineering lead, PhD in engineering) drives lab devices and AI/ML; Anjali (biomedical innovation expert) secured AUD $19M+ in research funding; Hayley (marketing head) accelerates commercialization with go-to-market strategies.[3] Pivotal moments include KPMG Tech Innovator 2024 and international market penetration, transforming lab concepts into scalable tools.[1]
Gelomics stands out in biotech through these key strengths:
Gelomics rides the 3D bioprinting and organ-on-chip trend, shifting drug development from unreliable animal models to AI-enhanced, human-precise in vitro platforms amid rising regulatory pressure for ethical alternatives (e.g., reducing animal use) and demand for faster, cheaper pipelines.[1][2][4][5] Timing aligns with post-2020 biotech boom in personalized medicine and regenerative therapies, where ECM stiffness control and vascular modeling address fibrosis, cancer, and cardiovascular gaps—market forces like sustainability mandates and AI integration favor scalable tools like LunaX.[5]
It influences the ecosystem by empowering CROs/pharmas with predictive models, accelerating discoveries (e.g., high-throughput screening, patient-specific therapies), and fostering cross-sector adoption, positioning Australia as a deep-tech biotech hub while cutting industry-wide costs and failures.[1][2]
Gelomics is primed for explosive growth by dominating ethical 3D cell culture, with LunaX expansions into bioprinting prosthetics, advanced disease modeling, and global partnerships likely driving revenue surges amid AI-biotech convergence.[2][4][5] Trends like regulatory pushes for non-animal testing, personalized healthcare, and microfluidics will amplify its edge, potentially evolving it into a regenerative medicine leader influencing pharma pipelines worldwide. This builds on its founding mission: transforming drug development into a faster, humane powerhouse.[1]
